Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26298301 | 1.00 | ADK (0.48) | ADKRETKDRADORA3ADORA2A | |
| SCHEMBL889732 | 1.00 | ADK (0.48) | ADKRETKDRADORA3ADORA2A | |
| SCHEMBL13889496 | 0.92 | ALDH1A1 (0.43) | ADKRETKDRSIGMAR1CSF1R | |
| SCHEMBL26298205 | 0.92 | ALDH1A1 (0.43) | ADKRETKDRSIGMAR1CSF1R | |
| SCHEMBL12601699 | 0.92 | ALDH1A1 (0.43) | ADKRETKDRSIGMAR1CSF1R | |
| SCHEMBL25996051 | 0.85 | ADK (0.54) | ADKADORA3ADORA2ASLC29A1 | |
| SCHEMBL1798411 | 0.85 | ADK (0.54) | ADKADORA3ADORA2ASLC29A1 | |
| SCHEMBL889728 | 0.85 | MAPT (0.41) | ADKRETKDRADORA3ADORA2A | |
| SCHEMBL23786511 | 0.84 | ADK (0.47) | ADKADORA3ADORA2ASLC29A1 | |
| SCHEMBL24686959 | 0.83 | ADK (0.51) | ADKADORA3ADORA2ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431366-B2 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2013-04-30 | — | — | US | disclosed |
| US-7943752-B2 | Modified oligonucleotides and applications thereof | Applied Biosystems, L.L.C. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | APPLERA CORPORATION | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | RNGTT, POLRMT, POLM | ADK 1877/4885RET 2589/4885KDR 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.